Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors (original) (raw)

References

  1. Aeder SE, Martin PM, Soh JW, Hussaini IM (2004) PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 23:9062–9069
    Article PubMed CAS Google Scholar
  2. Basu A, Lazo JS (1992) Sensitization of human cervical carcinoma cells to _cis_-diamminedichloroplatinum (II) by bryostatin 1. Cancer Res 52:3119–3124
    PubMed CAS Google Scholar
  3. Corbett AH, Fernald AW, Osheroff N (1993) Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation. Biochemistry 32:2090–2097
    Article PubMed CAS Google Scholar
  4. Dale IL, Bradshaw TD, Gescher A, Pettit GR (1989) Comparison of effects of bryostatins 1 and 2 and 12–_O_-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res 49:3242–3245
    PubMed CAS Google Scholar
  5. El-Rayes BF, Gadgeel S, Shields AF, Manza S, Lorusso P, Philip PA (2006) Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res 12:7059–7062
    Article PubMed CAS Google Scholar
  6. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199
    PubMed CAS Google Scholar
  7. Goodnight JE Jr, Moseley HS, Eilber FR, Sarna G, Morton DL (1979) _Cis_-dichlorodiammineplatinum (II) alone and combined with DTIC for treatment of disseminated malignant melanoma. Cancer Treat Rep 63:2005–2007
    PubMed Google Scholar
  8. Grunicke H, Hofmann J, Maly K, Goddard PM, Kelland LR, Morgan SE (1991) Enhancement of the antiproliferative effect of _cis_-diammine-dichloroplatinum (II) and other antitumor agents by inhibition of enzymes involved in growth factor signal transduction. In: Howell SB (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Plenum Press, New York, pp 161–172
    Google Scholar
  9. Grunicke H, Hofmann J, Utz I, Uberall F (1994) Role of protein kinases in antitumor drug resistance. Ann Hematol 69:S1–S6
    Article PubMed CAS Google Scholar
  10. Grunicke HH, Uberall F (1992) Protein kinase C modulation. Semin Cancer Biol 3:351–360
    PubMed CAS Google Scholar
  11. Gschwendt M, Furstenberger G, Rose-John S, Rogers M, Kittstein W, Pettit GR, Herald CL, Marks F (1988) Bryostatin 1, an activator of protein kinase C, mimics as well as inhibits biological effects of the phorbol ester TPA in vivo and in vitro. Carcinogenesis 9:555–562
    Article PubMed CAS Google Scholar
  12. Gschwendt M, Leibersperger H, Kittstein W, Marks F (1992) Protein kinase C zeta and eta in murine epidermis. TPA induces down-regulation of PKC eta but not PKC zeta. FEBS Lett 307:151–155
    Article PubMed CAS Google Scholar
  13. Hallahan DE, Virudachalam S, Sherman ML, Huberman E, Kufe DW, Weichselbaum RR (1991) Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. Cancer Res 51:4565–4569
    PubMed CAS Google Scholar
  14. Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL, Radda GK (1995) Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic spectroscopic study. Br J Cancer 72:998–1003
    PubMed CAS Google Scholar
  15. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ (1994) Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 12:553–559
    PubMed CAS Google Scholar
  16. Hofmann J, Doppler W, Jakob A, Maly K, Posch L, Uberall F, Grunicke HH (1988) Enhancement of the antiproliferative effect of _cis_-diamminedichloroplatinum (II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 42:382–388
    Article PubMed CAS Google Scholar
  17. Hornung RL, Pearson JW, Beckwith M, Longo DL (1992) Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res 52:101–107
    PubMed CAS Google Scholar
  18. Isonishi S, Andrews PA, Howell SB (1990) Increased sensitivity to _cis_-diamminedichloroplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-_O_-tetradecanoylphorbol 13-acetate. J Biol Chem 265:3623–3627
    PubMed CAS Google Scholar
  19. Jackson DN, Foster DA (2004) The enigmatic protein kinase C delta: complex roles in cell proliferation and survival. FASEB J 18:627–636
    Article PubMed CAS Google Scholar
  20. Jayson GC, Crowther D, Prendiville J, McGown AT, Schneid C, Stern P, Young R, Brenchley P, Chang J, Owens S et al (1995) A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72:461–468
    PubMed CAS Google Scholar
  21. Liebes L, Potmesil M, Kim T, Pease D, Buckley M, Fry D, Cho J, Adler H, Dar K, Zeleniuch-Jacquotte A, Hochster H (1998) Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Can Res 4:545–557
    CAS Google Scholar
  22. Masso-Welch PA, Winston JS, Edge S, Darcy KM, Asch H, Vaughan MM, Ip MM (2001) Altered expression and localization of PKC eta in human breast tumors. Breast Cancer Res Treat 68:211–223
    Article PubMed CAS Google Scholar
  23. Mohammad RM, Diwakaran H, Maki A, Emara MA, Pettit GR, Redman B, AL-Katib A (1995) Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 19:667–673
    Article PubMed CAS Google Scholar
  24. Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ (2004) Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 93:144–148
    Article PubMed CAS Google Scholar
  25. Osada SI, Hashimoto Y, Nomura S, Kohno Y, Chida K, Tajima O, Kubo K, Akimoto K, Koizumi H, Kitamura Y, Suzuki K, Ohno S, Kuroki T (1993) Predominant expression of nPKCη, a Ca2+-independent isoform of protein kinase C in epithelial tissues, in association with epithelial differentiation. Cell Growth Diff 4:167–175
    PubMed CAS Google Scholar
  26. Perego P, Casati G, Gambetta RA, Soranzo C, Zunino F (1993) Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells. Cancer Lett 72:53–58
    Article PubMed CAS Google Scholar
  27. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J (1982) Isolation and structure of bryostatin 1. J Am Chem Soc 104:6846–6848
    Article CAS Google Scholar
  28. Philip PA, Harris AL (1995) Potential for protein kinase C inhibitors in cancer therapy. In: Muggia FM (ed) Concepts, mechanisms and new targets for chemotherapy, 1st edn. Kluwer, Boston, pp 3–28
    Google Scholar
  29. Philip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F, Harris AL (1993) Phase I study of Bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J Natl Cancer Inst 85:1812–1818
    Article PubMed CAS Google Scholar
  30. Pollack IF, Kawecki S, Lazo JS (1996) Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 84:1024–1032
    Article PubMed CAS Google Scholar
  31. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M, Pettit GR (1993) A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68:418–424
    PubMed CAS Google Scholar
  32. Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S (2006) Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin’s) lymphoma. Clin Cancer Res 12:5809–5816
    Article PubMed CAS Google Scholar
  33. Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD (1991) Successful treatment of murine melanoma with bryostatin 1. Cancer Res 51:682–687
    PubMed CAS Google Scholar
  34. Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM (1996) The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res 56:2105–2111
    PubMed CAS Google Scholar
  35. Thompson CH, Macaulay VM, O’Byrne KJ, Kemp GJ, Wilner SM, Talbot DC, Harris AL, Radda GK (1996) Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br J Cancer 73:1161–1165
    PubMed CAS Google Scholar
  36. Trenn G, Pettit GR, Takayama H, Hu-Li J, Sitkovsky MV (1988) Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins. J Immunol 140:433–439
    PubMed CAS Google Scholar
  37. Varterasian M, Eilender D, Mohammad R, Chen B, Hulburd K, Rodriguez D, Pluda J, Valdivieso M, Al-Katib A (1996) Phase I trial of bryostatin 1 in relapsed lymphoma and CLL. Proc Am Soc Clin Oncol 15:481 (Abstr # 1526)
    Google Scholar
  38. Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy AL, Smith DL, Bernstein M (1999) A phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res 5:2344–2348
    PubMed CAS Google Scholar
  39. WHO (1979) Handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48
  40. Zhang R, Muller HJ, Kielassa K, Marks F, Gschwendt M (1994) Partial purification of a type eta protein kinase C from murine brain: separation from other protein kinase C isoenzymes and characterization. Biochem J 304:641–647
    Google Scholar
  41. Zhao M, Rudek MA, He P, Smith BD, Baker SD (2005) Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. Anal Biochem 33:143–148
    Article CAS Google Scholar

Download references